{"id":30039,"date":"2026-04-24T08:00:00","date_gmt":"2026-04-24T06:00:00","guid":{"rendered":"https:\/\/qlinea.com\/mfn_news\/q-linea-publish-the-annual-report-for-2025\/"},"modified":"2026-04-24T08:48:46","modified_gmt":"2026-04-24T06:48:46","slug":"q-linea-publish-the-annual-report-for-2025","status":"publish","type":"mfn_news","link":"https:\/\/qlinea.com\/us\/mfn_news\/q-linea-publish-the-annual-report-for-2025\/","title":{"rendered":"Q-linea publish the Annual report for 2025"},"content":{"rendered":"
\n

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2025 fiscal year has been published. The Annual Report is attached and can also be downloaded from the company’s website, <\/strong>www.qlinea.com<\/a><\/strong><\/p>\n<\/div>\n

\n

\n<\/div>\n

\n

For more information, please contact:<\/strong><\/p>\n

\n

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com<\/a><\/p>\n

Christer Samuelsson, CFO \/IR, Q-linea AB
Christer.Samuelsson@qlinea.com<\/a>
+46 (0) 70-600 15 20<\/p>\n<\/div>\n

\n

About Q-linea<\/strong><\/p>\n

\n

Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company’s core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.
Q-linea’s flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.<\/p>\n<\/div>\n

\n

This information is information that Q-linea is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-24 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

Qlinea 2025 ENG<\/a>
Q-linea-2025-12-31-0-sv<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2025 fiscal year has been published. The Annual Report is attached…<\/p>\n","protected":false},"template":"","class_list":["post-30039","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual-us","mfn-news-tag-mfn-lang-en-us","mfn-news-tag-mfn-type-ir-us","mfn-news-tag-mfn-us","mfn-news-tag-mfn-regulatory-us","mfn-news-tag-mfn-report-us","mfn-news-tag-mfn-regulatory-vpml-us"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/mfn_news\/30039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=30039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}